About edesa biotech - EDSA
Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.
EDSA At a Glance
Edesa Biotech, Inc.
100 Spy Court
Markham, Ontario L3R 5H6
| Phone | 1-289-800-9600 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -7,185,523.00 | |
| Sector | Health Technology | Employees | 17 | |
| Fiscal Year-end | 09 / 2026 | |||
| View SEC Filings |
EDSA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 5.527 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.603 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
EDSA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -422,677.824 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
EDSA Liquidity
| Current Ratio | 10.675 |
| Quick Ratio | 10.675 |
| Cash Ratio | 10.006 |
EDSA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -81.647 |
| Return on Equity | -99.57 |
| Return on Total Capital | -57.706 |
| Return on Invested Capital | -99.57 |
EDSA Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |